

InspireMD, Inc.  
Form 8-K  
September 16, 2014

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): September 16, 2014

**InspireMD, Inc.**

(Exact name of registrant as specified in its charter)

|  |                          |                                      |
|--|--------------------------|--------------------------------------|
| Delaware   | 001-35731                | 26-2123838                           |
| (State or other<br>jurisdiction<br>of incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

|  |            |
|--|------------|
| 321 Columbus Avenue                      |            |
| Boston, Massachusetts                    | 02116      |
| (Address of principal executive offices) | (Zip Code) |

Edgar Filing: InspireMD, Inc. - Form 8-K

Registrant's telephone number, including area code: (857) 453-6553

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01**

**Regulation FD Disclosure.**

Attached hereto as Exhibit 99.1 is a PowerPoint presentation that Professor Joachim Schofer, MD, will present on September 16, 2014, at the Transcatheter Cardiovascular Therapeutics (TCT) Conference, at the Walter E. Washington Convention Center in Washington, D.C., with respect to the results of InspireMD, Inc.'s CARENET (*CARotid Embolic protection using microNET*) trial.

The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 8.01**

**Other Events.**

On September 16, 2014, InspireMD, Inc. issued a press release announcing the results of InspireMD, Inc.'s CARENET trial. A copy of the press release is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

**Item 9.01**

**Financial Statements and Exhibits.**

(d)

Exhibits

| <b>Exhibit Number</b> | <b>Description</b>                     |
|-----------------------|--|
| 99.1                  | 2014 TCT Presentation                  |
| 99.2                  | Press Release dated September 16, 2014 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**inspiremd, inc.**

Date: September 16, 2014 By: /s/ Craig Shore  
Name: Craig Shore  
Title: Chief Financial  
Officer